INTRODUCTION: Cleavage of aggrecan between residues Glu(373)-Ala(374), which is believed to be a key event in aggrecan destruction in arthritic diseases, has been attributed to an enzymatic activity, aggrecanase. Two cartilage aggrecanases have been identified, aggrecanase-1 (ADAM-TS4) and aggrecanase-2 (ADAM-TS5) and both enzymes have been shown very efficiently to cleave soluble aggrecan at the Glu(373)-Ala(374) site. OBJECTIVE: To determine whether ADAM-TS4 and/or ADAM-TS5 are the aggrecanases responsible for aggrecan catabolism following interleukin-1 (IL-1) and tumor necrosis factor (TNF) treatment of bovine articular cartilage. RESULTS: (1) IL-1- and TNF-stimulated release of aggrecan was associated with cleavage of aggrecan within the C-terminus at the ADAM-TS4 and ADAM-TS5-sensitive sites, Glu(1480)-Gly(1481), Glu(1667)-Gly(1668), and Glu(1871)-Leu(1872). (2) The order of cleavage following IL-1 stimulation of cartilage explants was the same as when soluble aggrecan is digested with recombinant human ADAM-TS4 and ADAM-TS5. (3) Both constitutive and stimulated cleavage of aggrecan at the ADAM-TS4 and ADAM-TS5-sensitive sites in cartilage was blocked by a general metalloproteinase inhibitor but not by a MMP-specific inhibitor, and this inhibition correlated with inhibition of aggrecan release from cartilage. (4) PCR and Western blot analysis indicated that both ADAM-TS proteases are expressed in cartilage explants; ADAM-TS5 is constitutively expressed whereas ADAM-TS4 is induced following IL-1 and TNF treatment. (5) Immunodepletion of both ADAM-TS4 and ADAM-TS5 from bovine articular cartilage cultures following IL-1 stimulation resulted in a 90% reduction of aggrecanase activity in the culture medium. Copyright 2001 OsteoArthritis Research Society International.
INTRODUCTION: Cleavage of aggrecan between residues Glu(373)-Ala(374), which is believed to be a key event in aggrecan destruction in arthritic diseases, has been attributed to an enzymatic activity, aggrecanase. Two cartilage aggrecanases have been identified, aggrecanase-1 (ADAM-TS4) and aggrecanase-2 (ADAM-TS5) and both enzymes have been shown very efficiently to cleave soluble aggrecan at the Glu(373)-Ala(374) site. OBJECTIVE: To determine whether ADAM-TS4 and/or ADAM-TS5 are the aggrecanases responsible for aggrecan catabolism following interleukin-1 (IL-1) and tumor necrosis factor (TNF) treatment of bovinearticular cartilage. RESULTS: (1) IL-1- and TNF-stimulated release of aggrecan was associated with cleavage of aggrecan within the C-terminus at the ADAM-TS4 and ADAM-TS5-sensitive sites, Glu(1480)-Gly(1481), Glu(1667)-Gly(1668), and Glu(1871)-Leu(1872). (2) The order of cleavage following IL-1 stimulation of cartilage explants was the same as when soluble aggrecan is digested with recombinant humanADAM-TS4 and ADAM-TS5. (3) Both constitutive and stimulated cleavage of aggrecan at the ADAM-TS4 and ADAM-TS5-sensitive sites in cartilage was blocked by a general metalloproteinase inhibitor but not by a MMP-specific inhibitor, and this inhibition correlated with inhibition of aggrecan release from cartilage. (4) PCR and Western blot analysis indicated that both ADAM-TS proteases are expressed in cartilage explants; ADAM-TS5 is constitutively expressed whereas ADAM-TS4 is induced following IL-1 and TNF treatment. (5) Immunodepletion of both ADAM-TS4 and ADAM-TS5 from bovinearticular cartilage cultures following IL-1 stimulation resulted in a 90% reduction of aggrecanase activity in the culture medium. Copyright 2001 OsteoArthritis Research Society International.
Authors: Christopher G Wilson; Ashley W Palmer; Fengrong Zuo; Elsie Eugui; Stacy Wilson; Rebecca Mackenzie; John D Sandy; Marc E Levenston Journal: Matrix Biol Date: 2006-11-11 Impact factor: 11.583
Authors: Micky D Tortorella; Alfredo G Tomasselli; Karl J Mathis; Mark E Schnute; Scott S Woodard; Grace Munie; Jennifer M Williams; Nicole Caspers; Arthur J Wittwer; Anne-Marie Malfait; Huey-Sheng Shieh Journal: J Biol Chem Date: 2009-07-08 Impact factor: 5.157
Authors: Kimberly K Brown; Sandra A Heitmeyer; Erin B Hookfin; Lily Hsieh; Maria Buchalova; Yetunde O Taiwo; Michael J Janusz Journal: J Inflamm (Lond) Date: 2008-12-04 Impact factor: 4.981
Authors: S Jane Millward-Sadler; Patrick W Costello; Anthony J Freemont; Judith A Hoyland Journal: Arthritis Res Ther Date: 2009-05-12 Impact factor: 5.156
Authors: Claudine G James; Lee-Anne Stanton; Hanga Agoston; Veronica Ulici; T Michael Underhill; Frank Beier Journal: PLoS One Date: 2010-01-13 Impact factor: 3.240